The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity

  • Chung, Woo-Baek (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Youn, Ho-Joong (Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea)
  • Received : 2016.01.17
  • Accepted : 2016.05.20
  • Published : 2016.07.01
⟨ Previous Next ⟩

Abstract

Cardiotoxicity is a well-known complication following treatment with anthracyclines. However, they are still widely used in chemotherapy for breast cancer, lymphoma, leukemia, and sarcoma, among others. Patient clinical characteristics, such as age, sex, comorbidities, anthracycline dose and infusion schedule, and the combined anti-cancer agents used, are diverse among cancer types. It is difficult to recommend guidelines for the prevention or management of anthracycline-induced cardiotoxicity applicable to all cancer types. Therefore, anthracycline-induced cardiotoxicity remains a major limitation in the proper management of cancer patients treated with an anthracycline-combined regimen. Efforts have been extensive to determine the mechanism and treatment of anthracycline-induced cardiotoxicity. Because cardiotoxicity causes irreversible damage to the myocardium, prevention is a more effective approach than treatment of cardiotoxicity after symptomatic or asymptomatic cardiac dysfunction develops. This article will review the pathophysiological mechanisms of anthracycline-induced cardiotoxicity and strategies for protecting the myocardium from anthracycline.

Keywords

References

  1. Jung KW, Won YJ, Oh CM, et al. Prediction of cancer incidence and mortality in Korea, 2015. Cancer Res Treat 2015;47:142-148. https://doi.org/10.4143/crt.2015.066
  2. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231-2247. https://doi.org/10.1016/j.jacc.2009.02.050
  3. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010;102:14-25. https://doi.org/10.1093/jnci/djp440
  4. Kim SM, Kwak CH, Lee B, et al. A case of severe coronary spasm associated with 5-fluorouracil chemotherapy. Korean J Intern Med 2012;27:342-345. https://doi.org/10.3904/kjim.2012.27.3.342
  5. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 2014;64:938-945. https://doi.org/10.1016/j.jacc.2014.06.1167
  6. Angsutararux P, Luanpitpong S, Issaragrisil S. Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress. Oxid Med Cell Longev 2015;2015:795602.
  7. Chung WB, Yi JE, Jin JY, et al. Early cardiac function monitoring for detection of subclinical doxorubicin cardiotoxicity in young adult patients with breast cancer. J Breast Cancer 2013;16:178-183. https://doi.org/10.4048/jbc.2013.16.2.178
  8. Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011;107:1375-1380. https://doi.org/10.1016/j.amjcard.2011.01.006
  9. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131:1981-1988. https://doi.org/10.1161/CIRCULATIONAHA.114.013777
  10. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [Internet]. Bethesda (MD): National Cancer Institute, c2009 [cited 2016 May 14]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
  11. Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol 2010;56:1644-1650. https://doi.org/10.1016/j.jacc.2010.07.023
  12. Toro-Salazar OH, Ferranti J, Lorenzoni R, et al. Feasibility of echocardiographic techniques to detect subclinical cancer therapeutics-related cardiac dysfunction among high-dose patients when compared with cardiac magnetic resonance imaging. J Am Soc Echocardiogr 2016;29:119-131. https://doi.org/10.1016/j.echo.2015.10.008
  13. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23 Suppl 7:vii155-vii166.
  14. Corapcioglu F, Sarper N, Berk F, Sahin T, Zengin E, Demir H. Evaluation of anthracycline-induced early left ventricular dysfunction in children with cancer: a comparative study with echocardiography and multigated radionuclide angiography. Pediatr Hematol Oncol 2006;23:71-80. https://doi.org/10.1080/08880010500313603
  15. Lim CC, Zuppinger C, Guo X, et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 2004;279:8290-8299. https://doi.org/10.1074/jbc.M308033200
  16. Choi JY, Youn HJ, Kang JH, et al. Transthoracic echocardiographic assessment of adriamycin-induced cardiomyopathy in rats with a 15 MHz transducer. J Korean Soc Echocardiogr 2000;8:78-86. https://doi.org/10.4250/jkse.2000.8.1.78
  17. Choi YS, Park CS, Cho EJ, et al. The relation between acute adriamycin induced cardiomyopathy and apoptosis in rat: study using 15 MHz high frequency transducer. J Korean Soc Echocardiogr 2002;10:35-43. https://doi.org/10.4250/jkse.2002.10.2.35
  18. Uhm JS, Youn HJ, Park CS, et al. Comparison of adriamycin-induced cardiomyopathy in normotensive rats and spontaneously hypertensive rats. J Korean Soc Hypertens J 2006;12:23-30.
  19. Rochette L, Guenancia C, Gudjoncik A, et al. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends Pharmacol Sci 2015;36:326-348. https://doi.org/10.1016/j.tips.2015.03.005
  20. Salazar-Mendiguchia J, Gonzalez-Costello J, Roca J, Ariza-Sole A, Manito N, Cequier A. Anthracycline-mediated cardiomyopathy: basic molecular knowledge for the cardiologist. Arch Cardiol Mex 2014;84:218-223.
  21. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229. https://doi.org/10.1124/pr.56.2.6
  22. L'Ecuyer T, Sanjeev S, Thomas R, et al. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol 2006;291:H1273-H1280. https://doi.org/10.1152/ajpheart.00738.2005
  23. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 2012;52:1213-1225. https://doi.org/10.1016/j.yjmcc.2012.03.006
  24. Fu LX, Waagstein F, Hjalmarson A. A new insight into adriamycin-induced cardiotoxicity. Int J Cardiol 1990;29:15-20. https://doi.org/10.1016/0167-5273(90)90267-9
  25. Minotti G, Ronchi R, Salvatorelli E, Menna P, Cairo G. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 2001;61:8422-8428.
  26. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 2006;41:389-405. https://doi.org/10.1016/j.yjmcc.2006.06.009
  27. Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 2007;21:413-427. https://doi.org/10.1016/j.bbi.2006.11.004
  28. Chiosi E, Spina A, Sorrentino A, et al. Change in TNF-alpha receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death. J Interferon Cytokine Res 2007;27:589-597. https://doi.org/10.1089/jir.2006.0161
  29. Youn HJ, Kim HS, Jeon MH, et al. Induction of caspase-independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment. Mol Cell Biochem 2005;270:13-19. https://doi.org/10.1007/s11010-005-2541-2
  30. Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18:1639-1642. https://doi.org/10.1038/nm.2919
  31. Vejpongsa P, Yeh ET. Topoisomerase 2${\beta}$: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther 2014;95:45-52.
  32. Chung WB, Youn HJ, Choi YS, et al. The expression of cardiac ankyrin repeat protein in an animal model of adriamycin-induced cardiomyopathy. Korean Circ J 2008;38:455-461. https://doi.org/10.4070/kcj.2008.38.9.455
  33. Levkau B, Schafers M, Wohlschlaeger J, et al. Survivin determines cardiac function by controlling total cardiomyocyte number. Circulation 2008;117:1583-1593. https://doi.org/10.1161/CIRCULATIONAHA.107.734160
  34. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-2879. https://doi.org/10.1002/cncr.11407
  35. Menna P, Salvatorelli E, Minotti G. Cardiotoxicity of antitumor drugs. Chem Res Toxicol 2008;21:978-989. https://doi.org/10.1021/tx800002r
  36. Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009;10:391-399. https://doi.org/10.1016/S1470-2045(09)70042-7
  37. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-7819. https://doi.org/10.1200/JCO.2005.02.4091
  38. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:1231-1238. https://doi.org/10.1200/JCO.2007.13.5467
  39. Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 2013;31:3673-3680. https://doi.org/10.1200/JCO.2013.49.3205
  40. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J 2013;34:1102-1111. https://doi.org/10.1093/eurheartj/ehs181
  41. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 2014;63(25 Pt A):2751-2768. https://doi.org/10.1016/j.jacc.2014.01.073
  42. Tarr A, Stoebe S, Tuennemann J, et al. Early detection of cardiotoxicity by 2D and 3D deformation imaging in patients receiving chemotherapy. Echo Res Pract 2015;2:81-88. https://doi.org/10.1530/ERP-14-0084
  43. Poulin F, Thavendiranathan P. Cardiotoxicity due to chemotherapy: role of cardiac imaging. Curr Cardiol Rep 2015;17:564.
  44. Tamene AM, Masri C, Konety SH. Cardiovascular MR imaging in cardio-oncology. Magn Reson Imaging Clin N Am 2015;23:105-116. https://doi.org/10.1016/j.mric.2014.09.007
  45. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749-2754. https://doi.org/10.1161/01.CIR.0000130926.51766.CC
  46. Yu AF, Ky B. Roadmap for biomarkers of cancer therapy cardiotoxicity. Heart 2016;102:425-430. https://doi.org/10.1136/heartjnl-2015-307894
  47. de Azambuja E, Ameye L, Diaz M, et al. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil-or epirubicin-based chemotherapy. Eur J Cancer 2015;51:2517-2524. https://doi.org/10.1016/j.ejca.2015.08.011
  48. Park CS, Youn HJ, Cho EJ, et al. Cardioprotective effect of IGF-1 in mouse with adriamycin induced cardiomyopathy. Korean Circ J 2002;32:1116-1123. https://doi.org/10.4070/kcj.2002.32.12.1116
  49. Uhm JS, Chung WB, Yoon JS, Oh YS, Youn HJ. Effects of adriamycin and candesartan on the collagen and elastin of the aorta in rats. Clin Hypertens 2014;20:8. https://doi.org/10.1186/2056-5909-1-2
  50. Cardinale D, Bacchiani G, Beggiato M, Colombo A, Cipolla CM. Strategies to prevent and treat cardiovascular risk in cancer patients. Semin Oncol 2013;40:186-198. https://doi.org/10.1053/j.seminoncol.2013.01.008

Cited by

  1. Clinical Application of 2D Speckle Tracking Strain for Assessing Cardio-Toxicity in Oncology vol.1, pp.4, 2016, https://doi.org/10.3390/jfmk1040343
  2. Bone marrow-derived mesenchymal stem cells overexpressing miR-21 efficiently repair myocardial damage in rats vol.8, pp.17, 2016, https://doi.org/10.18632/oncotarget.16254
  3. Cardiac autonomic modulation induced by doxorubicin in a rodent model of colorectal cancer and the influence of fullerenol pretreatment vol.12, pp.7, 2016, https://doi.org/10.1371/journal.pone.0181632
  4. MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2 vol.15, pp.None, 2016, https://doi.org/10.1016/j.redox.2017.12.013
  5. Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society vol.26, pp.1, 2018, https://doi.org/10.4250/jcu.2018.26.1.1
  6. β-Lapachone protects against doxorubicin-induced nephrotoxicity via NAD+/AMPK/NF-kB in mice vol.392, pp.5, 2019, https://doi.org/10.1007/s00210-019-01619-0
  7. Critical Illness and Cardiac Dysfunction in Anthracycline-Exposed Pediatric Oncology Patients* : vol.20, pp.7, 2016, https://doi.org/10.1097/pcc.0000000000001915
  8. Clinical outcomes after transcatheter aortic valve replacement in cancer survivors treated with ionizing radiation vol.5, pp.None, 2019, https://doi.org/10.1186/s40959-019-0044-7
  9. Luteolin attenuates doxorubicin-induced cardiotoxicity by modulating the PHLPP1/AKT/Bcl-2 signalling pathway vol.8, pp.None, 2016, https://doi.org/10.7717/peerj.8845
  10. Cardioprotective Effects and Duration of Beta Blocker Therapy in Anthracycline-Treated Patients: A Systematic Review and Meta-analysis vol.20, pp.1, 2016, https://doi.org/10.1007/s12012-019-09558-1
  11. The Effects of Thiamine Hydrochloride on Cardiac Function, Redox Status and Morphometric Alterations in Doxorubicin-Treated Rats vol.20, pp.2, 2016, https://doi.org/10.1007/s12012-019-09536-7
  12. β‐LAPachone ameliorates doxorubicin‐induced cardiotoxicity via regulating autophagy and Nrf2 signalling pathways in mice vol.126, pp.4, 2016, https://doi.org/10.1111/bcpt.13340
  13. Cardiovascular Complications of Novel Anti-Cancer Immunotherapy: Old Problems from New Agents? vol.50, pp.9, 2016, https://doi.org/10.4070/kcj.2020.0158
  14. GPR91 Receptor Mediates Protection against Doxorubicin-Induced Cardiotoxicity without Altering Its Anticancer Efficacy. An In Vitro Study on H9C2 Cardiomyoblasts and Breast Cancer-Derived MCF-7 Cells vol.9, pp.10, 2020, https://doi.org/10.3390/cells9102177
  15. Clinical features of anthracycline‐induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single‐center, retrospective observ vol.1, pp.2, 2016, https://doi.org/10.1002/jha2.110
  16. Anthracycline Induced Cardiac Disorders in Childhood Acute Lymphoblastic Leukemia: A Single-Centre, Retrospective, Observational Study vol.12, pp.None, 2021, https://doi.org/10.3389/fphar.2021.598708
  17. Left Atrial Strain changes in patients with breast cancer during anthracycline therapy vol.330, pp.None, 2016, https://doi.org/10.1016/j.ijcard.2021.02.013
  18. Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin vol.10, pp.12, 2016, https://doi.org/10.1002/cam4.3956
  19. Genetic basis of anthracyclines cardiotoxicity: Literature review vol.6, pp.4, 2016, https://doi.org/10.29413/abs.2021-6.4.3
  20. Pera orange (Citrus sinensis) and Moro orange (Citrus sinensis (L.) Osbeck) juices attenuate left ventricular dysfunction and oxidative stress and improve myocardial energy metabolism in acute doxorub vol.91, pp.None, 2016, https://doi.org/10.1016/j.nut.2021.111350
  21. Cardioprotective effects of Talinum paniculatum (Jacq.) Gaertn. in doxorubicin-induced cardiotoxicity in hypertensive rats vol.281, pp.None, 2016, https://doi.org/10.1016/j.jep.2021.114568